Developing treatments for the diseases that are hardest to treat*

We wholly own a platform with the potential for treating a wide range of diseases — from cancers to inflammation-based diseases like arthritis and kidney disease. Endocyte technology is in late-stage clinical trials and is under review for conditional approval in Europe.

PLATFORM YIELDS MULTIPLE NEW SMDCs

PROGRAM / INDICATION PHASE DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3
ONCOLOGY – FOLATE RECEPTOR
Vintafolide (EC145)*   DRUG PAYLOAD: DAVLBH
Platinum Resistant Ovarian Cancer PHASE 3          
Non-small Cell Lung Cancer PHASE 2          
Triple Negative Breast Cancer PHASE 2          
Carboplatin/Paclitaxel Combination PHASE 1          
EC1456 DRUG PAYLOAD: Tubulysin-B
Solid Tumors PHASE 1          
Etarfolatide (EC20) DRUG PAYLOAD: Tc-99m
Folate Receptor Positive Tumors PHASE 3          
ONCOLOGY – PROSTATE SPECIFIC MEMBRANE ANTIGEN
EC1169 DRUG PAYLOAD: Tubulysin-B
Prostate Cancer PRECLINICAL          
EC0652 DRUG PAYLOAD: Tc-99m
Prostate Tumors PRECLINICAL          
INFLAMMATION – FOLATE RECEPTOR
EC1669 DRUG PAYLOAD: Aminopterin
Inflammation PRECLINICAL          

 SMDC  Companion Imaging Diagnostic

Endocyte technology has the potential for broad application

Our technology has the potential to treat the types of cancers found in over 40% of cancer patients worldwide.1 Our lead companion imaging agent and SMDC target the folate receptor, which is frequently expressed in some of the most prevalent, and difficult to treat, solid tumor cancer indications, including non-small cell lung, breast, colorectal, kidney, endometrial, and ovarian cancers.

Using our flexible SMDC technology platform, we are also developing precision therapies for other cancer-cell receptors and diseases. One of our imaging agents, EC0652, is being developed to non-invasively identify tumors that overexpress prostate-specific membrane antigen (PSMA) receptors, and is currently being evaluated in a Phase 1 trial for patients with advanced prostate cancer. 

An engine for new drug development

With the advent of an innovative form of delivery, more research and development can focus on new potent cytotoxic drugs.

What’s more, our modular technology is being studied with different drugs or a combination of drugs in a variety of diseases, allowing for potential expansion into lower-expressing cancer indications and other difficult-to-treat diseases.

Our pipeline and the future of precision medicine

Three new SMDCs are now entering clinical trials: one is a prostate-specific membrane antigen (PSMA)-targeted drug, another is a candidate for inflammation indication, and the third is designed to deliver a potent chemotherapy drug called tubulysin using our second-generation guidance system. 

* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

1. Reference: Low PS, Klaratne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009 Jun;13(3):256-262. doi: 10.1016/j.cbpa.2009.03.022. Epub 2009 May 4.